GET DAILY SIGNALSMesa Laboratories (MLAB) Reports Q2 Earnings and Delivers First Full-Year Guidance
Key Takeaways
- Revenue increased 2.6% year over year to $62.3 million, coming in modestly above Wall Street’s consensus estimate.
- Diluted EPS landed at $0.75, missing analyst forecasts, while net income rose 75.3% to $4.3 million.
- Adjusted EBITDA grew 21.1% to $17.3 million, expanding the margin to 27.8%.
- Sterilization and Disinfection Control posted roughly 14.6% organic growth, whereas Biopharmaceutical Development fell 8.2% due to export controls and shipment timing.
- Management provided its initial full-year outlook: fiscal 2027 revenue of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million.
- The board approved a new $40 million share repurchase authorization, and the company finished the quarter with 1.75x total net leverage.
Earnings Context and Why It Matters
Mesa Laboratories, which provides quality control solutions and life science tools for regulated pharmaceutical, healthcare, and medical device markets, wrapped up its second fiscal quarter ended September 30, 2026 on a notable note. After several periods focused on improving delivery reliability and refining its portfolio, the report marked the first time the company issued formal full-year guidance. That step carries weight because it turns management’s turnaround narrative into specific targets. From what I see, investors are paying close attention to whether stronger profitability in the core quality control businesses can offset softer trends in Biopharmaceutical Development and the intentional scaling back of Clinical Genomics, now run primarily for cash generation.
Reported Results
For the second fiscal quarter of 2027, MLAB posted revenue of $62.3 million, up 2.6% from the prior-year quarter and slightly ahead of the roughly $61.6 million consensus estimate. Net income climbed 75.3% to $4.3 million, resulting in diluted EPS of $0.75 that came in below expectations. Operating income rose 77.6% to $8.4 million.
Profitability showed clear improvement. Gross margin widened by about 250 basis points to 64.0%, and adjusted EBITDA increased 21.1% to $17.3 million, or 27.8% of revenue. Segment revenue included $25.3 million from Sterilization and Disinfection Control, $14.1 million from Calibration Solutions, $12.8 million from Biopharmaceutical Development, and $10.2 million from Clinical Genomics.
Management also introduced fiscal 2027 guidance for the first time, targeting revenue of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million. That implies adjusted EBITDA growth of roughly 5% to 8% alongside revenue growth of about 0% to 2%.
Market Reaction and Investor Sentiment
MLAB shares closed at $127.82 on November 9, 2026, with modest weakness during the regular session and further softness in after-hours trading. The muted-to-negative response seemed tied to the EPS miss, even though revenue topped estimates and profitability expanded meaningfully. Investors appeared to balance the higher-quality earnings growth against ongoing concerns in Biopharmaceutical Development, where export-control delays and shipments that missed the quarter-end weighed on results, along with the continued restructuring of Clinical Genomics. The introduction of full-year guidance and the new buyback program were seen as constructive, yet the market stayed focused on near-term revenue visibility in the faster-growing areas.
Forward Outlook and Key Factors to Monitor
The company’s first full-year guidance establishes a clear baseline, but achieving it will depend on several variables. Management expects revenue growth to be uneven, with third-quarter revenue roughly flat year over year, largely due to lower Clinical Genomics revenue. Excluding that segment, continued growth is anticipated.
A savings plan announced in October is projected to cut annualized operating costs by about $9.3 million, with roughly $4.3 million reinvested in commercial capacity and key corporate roles, for a net reduction near $5 million. I’m watching closely how quickly those savings materialize and whether the reinvestment supports growth in Sterilization and Disinfection Control and Calibration Solutions.
Delivery reliability in Sterilization and Disinfection Control continues to be a focus area. Although that business grew in the mid-teens organically, management noted that one key product line tied to past-due backlog is only partially resolved. In Biopharmaceutical Development, the next-generation Gyrolab platform remains slated for a fiscal 2028 launch, and orders that slipped past quarter-end are expected to be recognized in the third quarter. Capital allocation will also draw attention, given the newly authorized $40 million repurchase program, ongoing debt reduction, and potential small tuck-in acquisitions that could shape how MLAB deploys its improving cash flow.
Using AI Tools in My Research Process
When analyzing names like MLAB, I often run quick checks through Tickeron’s AI Screener to compare momentum and fundamentals against peers. It helps surface relevant patterns and filter ideas efficiently without replacing deeper fundamental work. This kind of tool fits naturally into a routine review of sector trends and valuation context.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MLAB in upward trend: price rose above 50-day moving average on November 10, 2026
MLAB moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 33 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on MLAB as a result. In 63 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for MLAB just turned positive on November 10, 2026. Looking at past instances where MLAB's MACD turned positive, the stock continued to rise in 37 of 53 cases over the following month. The odds of a continued upward trend are 70%.
Following a +3.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLAB advanced for three days, in 223 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for MLAB moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 22 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for MLAB crossed bearishly below the 50-day moving average on November 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
MLAB broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MLAB entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. MLAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.802) is normal, around the industry mean (1.448). MLAB has a moderately high P/E Ratio (150.882) as compared to the industry average of (5.350). Projected Growth (PEG Ratio) (1.390) is also within normal values, averaging (5.470). Dividend Yield (0.005) settles around the average of (0.012) among similar stocks. P/S Ratio (2.818) is also within normal values, averaging (32.028).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of computer-based electronic measurement instruments
Industry ElectronicEquipmentInstruments